CAMBRIDGE, Mass., Nov. 17, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI), an innovative cancer drug discovery and development company, today announced that Jeffrey Tong, Ph.D., vice president, corporate and product development, will present an overview of IPI-504 (retaspimycin hydrochloride), the company's intravenous heat shock protein 90 (Hsp90) chaperone inhibitor, at the Therapeutic Area Partnerships event tomorrow, November 18, 2009 at 3:30 p.m. EST. The conference, being held November 17-19, in Boston, showcases Windhover and Campbell Alliance's 2009 "Top 10 Projects to Watch" and partnership opportunities in oncology.
"Infinity is dedicated to the innovative discovery and development of important, new cancer therapies, and we are pleased that our Hsp90 chaperone inhibitor program is being recognized as a leader in this important field," said Dr. Tong. "We are actively developing IPI-504 in a range of major cancer indications, and are looking forward to making further clinical progress in 2010. We believe our program represents a strong strategic collaboration opportunity."
Infinity's Hsp90 Chaperone Inhibitor Program
Infinity is making progress in the clinical evaluation of its family of Hsp90 chaperone inhibitors, IPI-504 and orally administered IPI-493, in multiple cancer indications. Infinity is enrolling patients in a Phase 2 clinical study of IPI-504 in combination with Herceptin(R) (trastuzumab) in patients with HER2-positive metastatic breast cancer, and anticipates presenting preliminary data from this study in 2010. Infinity is also enrolling patients with non-small cell lung cancer (NSCLC) in a Phase 1b study evaluating IPI-504 in combination with Taxotere(R) (docetaxel). Infinity previously announced preliminary single-agent activity of IPI-504 in the Phase 2 portion of a study in patients with NSCLC; Infinity plans to publish the full data from this study and initiate further clinical development of IPI-504 in NSCLC in 2010. Infinity also anticipates initiating a Phase 2 clinical trial of IPI-504 in patients with advanced, dedifferentiated liposarcoma in 2010. Infinity's oral agent, IPI-493, is currently being evaluated in a Phase 1 dose-escalation study in patients with advanced solid tumors. Infinity anticipates presenting preliminary data from this Phase 1 study and conducting further clinical development of IPI-493 in 2010.
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative cancer drug discovery and development company seeking to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging cancer pathways. Infinity's two most advanced programs in Hsp90 chaperone inhibition and Hedgehog signaling pathway inhibition are evidence of its innovative approach to oncology drug discovery and development. For more information on Infinity, please refer to the company's website at http://www.infi.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding the utility of Hsp90 chaperone inhibitors, including IPI-504 and IPI-493, in treating various types of cancer, the commencement of additional clinical trials of IPI-504 and IPI-493, and the presentation or publication of clinical data for IPI-504 and IPI-493. Such statements are subject to numerous factors, risks and uncertainties that may cause actual events or results to differ materially from the company's current expectations. For example, there can be no guarantee that IPI-504 and IPI-493 will successfully complete necessary preclinical and clinical development phases. In particular, management's expectations could be affected by risks and uncertainties relating to: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities and investigational review boards at clinical trial sites; Infinity's ability to enroll patients in its clinical trials; unplanned cash requirements and expenditures; and Infinity's ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates it is developing. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" included in Infinity's quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 9, 2009. Further, any forward-looking statements contained in this press release speak only as of the date hereof, and Infinity expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Herceptin(R) and Taxotere(R) are registered trademarks of Genentech, Inc. and sanofi-aventis llc, respectively.